medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2004, Number 3

<< Back Next >>

Alerg Asma Inmunol Pediatr 2004; 13 (3)

The aspirin induced-respiratory desease

Fuentes BA, García CM, Terán JL

Language: Spanish
References: 34
Page: 99-103
PDF size: 121.75 Kb.


ABSTRACT

The aspirin-induced respiratory disease is a distinct syndrome that differs from classic asthma in the persistence and severity of its nasobronchial symptoms and the relationship with aspirin. The exact mechanism that leads to those reactions is unknown but there is evidence pointing at some metabolic derangements of the arachidonic acid pathway. The possible role of chemokines still needs to be elucidated.


REFERENCES

  1. Global Initiative for Asthma revised 2002.

  2. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225-32.

  3. Hirshberg H. Mittheilung über einen von debenwirkung des aspirin. Deutsche Med Wschr 1902; i: 416-7.

  4. Widal M, Abrani P, Lermoyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922; 30: 189-92.

  5. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Int Med 1968; 68: 975-83.

  6. Szczeklik A, Stevenson D. Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003: 111(5).

  7. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328: 434.

  8. Stevenson D, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001; 87: 177-80.

  9. Nizankowska E, Duplaga M, Bochenek G, Szczeklik A. Clinical course of aspirin-induced asthma. Results of AIANE. In: Szczeklik A, Gryglewski R, Vane J, editors. Eicosanoids, aspirin and asthma. New York: Marcel Dekker; 1998: 451-471.

  10. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588-93.

  11. Sanak M, Sampson A. Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999; 29: 306-313.

  12. Sousa A, Parikh A, Scadding G et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347: 1493-99.

  13. Sestini P, Armetti L, Gambaro G et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153: 572-5.

  14. Ferreri N, Howland W, Stevenson D, Spiegelberg H. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988; 137: 847-854.

  15. Picado C, Ramis I, Roselló J et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992; 145: 65-69.

  16. Hamilos D, Leung D, Wood R et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 1995; 96: 537-44.

  17. Varga E, Jacobson M, Masuyama K et al. Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999; 14: 610-615.

  18. Grzelewska-Rzymowska I, Rozniecki J, Szmidt M, Kowalski M. Asthma with aspirin intolerance. Clinical entity or coincidence of nonspecific bronchial hyperreactivity and aspirin intolerance. Allergol Immunopathol Madr 1981; 9: 533-538.

  19. Picado C. Nasal polyposis. Clin Exp Allergy Rev 2001; 1: 163-165.

  20. Steinke J, Bradley D, Arango P et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: Importance to eosinophilia and asthma. J Allergy Clin Immunol 2003; 111: 342-9.

  21. Sladek K, Dworski R, Soja J et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149: 940-6.

  22. Nasser S, Lee T. Leukotrienes in aspirin-sensitive asthma. In: Szczeklik A, Gryglewski R, Vane J (editors). Eicosanoids, aspirin and asthma. New York: Marcel Dekker; 1998: 317-36.

  23. Cowburn A, Sladek K, Soja J et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-846.

  24. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23: 290-6.

  25. Kawagishi Y, Mita H, Taniguci M et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109: 936-42.

  26. Nasser S, Pfister R, Christie P et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153: 90-6.

  27. Kowalski M, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26: 807-14.

  28. Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax 2000; 55 (Suppl 2): S45-S47.

  29. Brauer J, Amelung P, Meyers D et al. Association of asthma susceptibility with a polymorphism in the leukotriene C4 synthase gene. Am J Respir Crit Care Med 1999; 159: A650.

  30. Teran LM. CCL chemokines and asthma. Immunol Today 2000; 21: 235-242.

  31. Gutierrez-Ramos J, Lloyd C, Gonzalo J. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today 1999; 20: 500-504.

  32. Owen C. Chemokine receptors in airway disease: which receptors to target? Pulmonary Pharmacology & Therapeutics 2001; 14: 193-202.

  33. Bandeira-Melo C, Bozza P, Weller P. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002; 109: 393-400.

  34. Pods R, Ross D, van Hulst S et al. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58: 1165-70.




2020     |     www.medigraphic.com